Interleukin-16 network in inflammation and allergy

Allergy and Asthma Proceedings

Volumn 23, Issue 2, 2002, Pages 103-108

  Conti, Pio ^a   Kempuraj, Duraisamy ^b   Kandere, Kristiana ^b   Di Gioacchino, Mario ^a   Reale, Marcella ^a   Barbacane, Renato C ^a   Castellani, Maria L ^a   Mortari, Umberto ^c   Boucher, William ^b   Letourneau, Richard ^b   Theoharides, Theoharis C ^b  

^a UNIVERSITY OF CHIETI   (Italy)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Merck Research Laboratories   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; INTERLEUKIN 16;

HUMAN; HYPERSENSITIVITY; IMMUNOLOGY; INFLAMMATION; REVIEW; T LYMPHOCYTE;

ANTIGENS, CD4; HUMANS; HYPERSENSITIVITY; INFLAMMATION; INTERLEUKIN-16; T-LYMPHOCYTES;

EID: 0036516989     PISSN: 10885412     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Center DM, and Cruikshank WW. Modulation of lymphocyte migration by human lymphokines. I. Identification and characterization of chemoattractant activity for lymphocytes from mitogen-stimulation mononuclcar cells J Immunol 128:2562-2568, 1982.
2. Cruikshank WW, and Center DM. Modulation of lymphocyte migration by human lymphokines II Purification of a lymphocyte factor (LCF). J Immunol 128.2569-2571, 1982.
3. Oppenheim JJ, Lloyd A, Taub D, et al. Active properties of chemokines and their receptors. Int J Immunopathol Pharmacol 7:219-220, 1994.
4. Center DM, Kornfeld H, and Cruikshank WW. Interleukin 16 and its function as a CD4 ligand. Immunol. Today 17:476-480, 1996.
5. Hessel EM, Cruikshank WW, Van Ark I, et al. Involvement of IL-16 in the induction of airway hyper-responsiveness and up-regulation of IgE in a murine model of allergic asthma. J Immunol 160:2998-3005, 1998.
6. Kaser A, Dunzendorfer S, Offner FA, et al. A role for interleukin 16 in the cross talk between dendritic cells and T cells. J Immunol 163:3232-3238, 1999.
7. Kaser A, Dunzendorfer S, Offner FA, et al. B lymphocyte-derived IL-16 attracts dendritic cells and Th cells. J Immunol 165:2474-2480, 2000.
8. Cruikshank WW, Center DM, Nisar N, et al. Molecular and functional analysis of a lymphocyte chemoattractant factor: association of biologic function with CD4 expression. Proc Natl Acad Sci USA 91.5109-5113, 1994.
9. Maciaszek JW, Parada NA, Cruikshank WW, et al. IL-16 represses HIV-1 promoter activity J Immunol 158:5-8, 1997.
10. Arima M., Plitt J, Stellato C, et al. Expression of interlekin-16 by human epithelial cells. Inhibition by dexamethasone. Am J Respir Cell Mol Biol 21:684-692, 1999.
11. Cruikshank WW, Greenstein WW, Theodore AC, and Center DM. Lymphocyte chemoattiactant factor induces CD4-dependent intracytoplasmic signaling in lymphocytes. J Immunol 146:2928-2934, 1991.
12. Ryan TC, Cruikshank WW, Kornfeld H, et al. The CD4-associated tyrosine kinase p561ck is required for lymphocyte chemoattractant factor-induced T lymphocyte migration. J Biol Chem 270:17081-17086, 1995.
13. Parada NA, Cruikshank WW, Dams HL, et al. IL-16 and other CD4 ligand-induced migration is dependent upon protein kinase C. Cell Immunol 168.100-106, 1996.
14. Moretti S, carli P, Spallanzani A. et al. Fibrogenic cytokines in cutaneous mucosal inflammatory models. Int J Immunopathol Pharmacol 10:89-90, 1997.
15. Cruikshank WW, Berman JS, Theodore AC, et al Lymphokine activation of T4+ T lymphocytes and monocytes. J Immunol 138: 3817-3823, 1987.
16. Cruikshank WW, Lim K, Theodore AC, et al. IL-16 inhibition of CDS-dependent lymphocyte activation and proliferation. J Immunol 157:5240-5248, 1996.
17. Conti P, and Theoharides TC. Monocyte chemotactic protein (MCP-1) is active on mast cells and causes clump formation. Int J Immunopathol Pharmacol 7 149-151, 1994.
18. Yoshimoto T, Wang CR, Yoneto T, et al. Role of IL-16 in delayed-type hypersensitivity reaction. Blood 95:2869-2874, 2000.
19. Mathy NL, Bnnert N, Norley SG, and Kurth R. Cutting edge: CD4 is not required for the functional activity of IL-16. J Immunol 164: 4429-4432, 2000.
20. Conti P, Kampuraj SD, Boucher W, et al. Mechanism by which IL-16 generated by mast cells mediates allergic inflammation. Int J Immunopathol Pharmacol 14:1-4, 2001.
21. Cruikshank WW, Kornfeld H, and Center DM Interleukin-16. J Leukoc Biol 67:757-766, 2000.
22. Contino R, Cassano N, Rossini M, et al. Mast cell subpopulations in chronic idiopatic urticaria. Int J Immunopathol Pharmacol 10:65-68, 1997.
23. Bos JD. Immunology of atopic dermatitis. Int J Immunopathol Pharmacol 10:91-92, 1997.
24. DiGioacchino M, Cavallucci E, Di Sciascio MB, et al. Allergen immunotherapy:an effective immune-modifier. Int J Immunopathol Pharmacol 12:1-6, 1999.
25. Theodore AC, Center DM, Nicoll J, et al. CD4 ligand IL-16 inhibits the mixed lymphocyte reaction J Immunol 157:1958-1964, 1996.
26. Hidi R, Riches V, Al-Ali M, et al. Role of B7-CD28/CTLA-4 costimulation and NF-kappa B in allergen-induced T cell chemotaxis by IL-16 and RANTES. J Immunol 164:412-418, 2000
27. Pinsonneault S, Bassam SE, Mazer B, et al. IL-16 inhibits IL-5 production by antigen-stimulated T cells in atopic subjects. J Allergy Clin Immunol 107:477-482, 2001.
28. Ferlat S, Bottex-Gauthier C, Li M, et al. Effects of a synthetic immunomodulator on the regulation of gamma interferon and interleukin 10 production during Salmonella sepsis in ITYs mice. Int J Immunopathol Pharmacol 10:167-174, 1997.
29. Krug N, Cruikshank WW, Tschernig T, et al. Interleukin-16 and T cell chemoattractant activity in bronchoalveolar lavage 24 hours after allergen challenge in asthma. Am J Respir Crit Care Med 162:105-111, 2000.
30. Laberge S, Pinsonneault S, Varga EM, et al. Increased expression of TL-16 immunoreactivity in bronchial mucosa after segmental allergen challenge in patients with asthma. J Allergy Clin Immunol 106:293-301, 2000
31. Duskova M, Dusek L, Ciz M, et al. the influence of some immunosupressive drugs on the metabolic activity of human phagocytes and lymphocytes in vitro. Int J Immunopathol Pharmacol 11:117-138, 1998.
32. Kramer MF, Ostertag P, Pfrogner E, and Rasp G. Nasal IL-16 and MIP-1alpha in late-phase allergic response. Allergy Asthma Proc 22:127-132, 2001.
33. Conti P, and Di Gioacchino M. MCP-1 and RANTES are mediators of acute and chronic inflammation. Allergy Asthma Proc 22:133-137, 2001.
34. De Bie JJ, Henricks PA, Cruikshank WW, et al. Effect of interleukin-16-blocking peptide on parameters of allergic asthma in a murine model. Eur J Pharmacol 383:189-196, 1999.
35. Mathy NL, Scheue W, Lanzendorfer M, et al. Interleukin-16 stimulates the expression and production of pro-inflammatory cytokines by human monocytes. Immunology 100:63-69, 2000.
36. Reale M, Frydas S, Barbacane RC, et al. Generation of monocyte chemotactic protein (MCP-1) by rat peritoneal mast cells after LPS or TNF-alpha activation. Int J Immunopathol Pharmacol 9:109-112, 1996.
37. Erroi A, Demetri MT, Salmona M, and Ghezzi P. Modulation of TNF production in a rat mast cell line (RBL) and monocyte (THP-1) by cAMP and glucocorticoids. Int J Immunopathol Pharmacol 11:17-22, 1998.
38. Arima M, Plitt J, Stellato C, et al. Expression of interleukin-16 by human epithelial cell. Inhibition by dexamethasone. Am J Respir Cell Mol Biol 21:684-692, 1999.
39. Fujita T, Matsumoto Y, Hirai I, et al. Immunosuppressive effect on T cell activation by interleukin-16-cDNA-transfected human squamous cell line. Cell Immunol 202:54-60, 2000.
40. Seegert D, Rosenstiel P, Pfahler H, et al. Increased expression of IL-16 in inflammatory bowel disease. Gut 48:326-332, 2001.
41. Mashikian MV, Tarpy RE, Saukkonen JJ, et al. Identification of IL-16 as the lymphocyte chemotactic activity in the bronchoalveolar lavage fluid of histamine-challenged asthmatic patients. J Allergy Clin Immunol 101:786-792, 1998.
42. Ameglio F, Bonifati C, Fazio M, et al. Levels of IL-1a, IL-6, IL-8 1, IL-8 1, IL-8 1, IL-8 in organ culture supernatants of psoriatic lesional skin Int J Immunopathol Pharmacol 10.83-84, 1997
43. Laberge S, Pinsonneault S, Ernst P, et al. Phenotype of IL-16-producing cells in bronchial mucosa: evidence for the human eosinophil and mast cell as cellular sources of IL-16 in asthma. Int Arch Allergy Immunol 119:120-125, 1999.
44. Hessel EM, Cruikshank WW, Van Ark I, et al. Involvement of IL-16 in the induction of airway hyper-responsiveness and up-regulation ot IgE in a murine model of allergic asthma. J Immunol 160:2998-3005, 1998.
45. Brezinska-Blaszczyk E, and Olejnik AK Intestinal mucosa-associated bacteria modulate rat mast cell reactivity. Int J Immunopathol Pharmacol 12:31-36, 1999.
46. Taylor ML, and Metcalfe DD, Mast cells in allergy and host defense Allergy Asthma Proc 22:115-119, 2001.
47. Graziano FM, Stahl JL, Cook EB, and Barney NP. Conjuntival mast cell in ocular allergic disease. Allergy Asthma Proc 22:121-126, 2001.
48. Sciaky D, Brazer W, Center DM, et al. Cultured human fibroblasts express constitutive IL-16 mRNA: cytokine induction of active IL-16 protein synthesis through a caspace-3-dependent mechanism. J Immunol 164:3806-3814, 2000.
49. Kempuraj D, Saito H, Kaneko A. et al. Characterization of mast cell-committed progenitors present in human umbilical cord blood Blood 93:3338-3346, 1999.
50. Yanagida M, Fukamachi H, Ohgami K, et al. Effects of T-helper 2 type cytokines, IL-3, IL-4, IL-5, and IL-6 on the survival of cultured human mast cells. Blood 86.3705-3714, 1995.
51. Chosay JG, Winterrowd GE, Shields SK, et al. Novel expression of functionalA4, 131, and B7 integrins on neutrophils in bone marrow, blood, and inflamed mouse pleural cavity. Int J Immunopathol Pharmacol 11.1-10, 1998.
52. Ameglio F, Bonifati C, Fazio M, et al. Levels of IL-1a, IL-6 a, IL-6 a, IL-6 a, IL-6 and IL-8 in organ culture supernatants of psoriatic lesional skin. Int J Immunopathol Pharmacol 10:83-84, 1997.
53. Moretti S, Carli P, Spallanzani A, et al. Fibrogenic cytokines in cutaneous-mucosal inflammatory models. Int J Immunopathol Pharmacol 10:89, 1997.
54. Mier JW, Gollob JA, and Atkins MB. Interleukin-12, a new antitumor Cytokine. Int J Immunopathol Pharmacol 11:109-116, 1998
55. Frydas S, Reale M, Barbacane RC, et al. Generation of monocyte chemotactic protein-1 (MCP-1) and TNF-a in mouse serum from trichinellosis. Int J Immunopathol Pharmacol 10:23-26, 1997.
56. Pastore S, Fanales-Belasio E, Albaneso C, et al. Keratinocytes from atopic dermatitis patients produce increased amounts of GM-CSF. Int J Immunopathol Pharmacol 10.93-95, 1997.
57. Frydas S, Rallis T, Theodorides I, et al. Trichinella spiralis infection is mediated by MCP1 and MIP-2, while Echinococcus granulosus is mediated strongly by MCP-1, but not MIP-2. Int J Immunopathol Pharmacol 13:21-26, 2000